Drug Trial Radar · NCT06953089
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Jul 18, 2025
Primary completion
Jun 30, 2030
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- DualityBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Conditions
- Solid Tumors
Interventions
DB-1311/BNT324Drug
Administered I.V.
BNT327Drug
Administered I.V.
DB-1305/BNT325Drug
Administered I.V.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants with Dose Limiting Toxicities (DLTs).Time frame: During the DLT evaluation period, i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days
- Part 1: Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs)Time frame: up to follow up period, e.g. up to 72 months.
- Part 2: Objective response rate (ORR), defined as the proportion of participants in whom a confirmed Complete response (CR) or PR is observed as best overall response by arm and dose level. (Arm 1-9).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
- ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per PCWG3-modified RECIST v1.1 as assessed by investigator) (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Locations
37 sites in 4 countries. Site status is shown where the registry gives one.
USA06-0
Los Angeles, California · Recruiting
USA16-0
Los Angeles, California · Recruiting
USA01-0
Wheat Ridge, Colorado · Recruiting
USA08-0
Florida City, Florida · Recruiting
USA10-0
Atlanta, Georgia · Recruiting
USA11-0
Bethesda, Maryland · Recruiting
USA14-0
Lincoln, Nebraska · Recruiting
USA04-0
New York, New York · Recruiting
USA15-0
Portland, Oregon · Recruiting
USA03-0
Charleston, South Carolina · Recruiting
USA13-0
Anderson, Texas · Recruiting
USA12-0
Houston, Texas · Recruiting
USA05-0
Virginia Beach, Virginia · Recruiting
USA09-0
Puyallup, Washington · Recruiting
USA07-0
Spokane, Washington · Recruiting
AUS07-0
North Sydney, New South Wales, Australia · Recruiting
AUS06-0
Benowa, Queensland, Australia · Recruiting
AUS04-0
Birtinya, Queensland, Australia · Recruiting
AUS05-0
Adelaide, South Australia, Australia · Recruiting
CHN02-0
Beijing, Beijing Municipality, China · Recruiting
CHN13-0
Beijing, Beijing Municipality, China · Recruiting
CHN23-0
Beijing, Beijing Municipality, China · Recruiting
CHN17-0
Dongguan, Guangdong, China · Recruiting
CHN06-0
Henan, Henan, China · Recruiting
CHN12-0
Xinxiang, Henan, China · Recruiting
CHN04-0
Hubei, Hubei, China · Recruiting
CHN26-0
Wuhan, Hubei, China · Recruiting
CHN34-0
Wuhan, Hubei, China · Recruiting
CHN11-0
Changsha, Hunan, China · Recruiting
CHN16-0
Xuzhou, Jiangsu, China · Recruiting
CHN35-0
Shenyang, Liaoning, China · Recruiting
CHN25-0
Xi'an, Shaanxi, China · Recruiting
CHN04-0
Shanghai, Shanghai Municipality, China · Recruiting
CHN01-0
Shanghai, Shanghai Municipality, China · Recruiting
CHN24-0
Chengdu, Sichuan, China · Recruiting
TWN01-0
Taipei, Taipei, Taiwan · Recruiting
TWN02-0
Taipei, Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.